Rhizen Pharmaceuticals
- Health
Rhizen Pharmaceuticals AG Announces That Its Partnered Asset, Umbralisib (UKONIQ™), Has Received US FDA Accelerated Approval for Adult Patients With Relapsed or Refractory MZL & FL
Basel, Switzerland: Umbralisib (UKONIQ™) granted accelerated approval by US FDA for the treatment of adult patients with relapsed or refractory…
Read More » - Health
Rhizen Pharmaceuticals SA Announces Presentation of the Interim Results of the Phase I/II study of Tenalisib (RP6530) in Combination with Romidepsin in Relapsed/Refractory T-cell Lymphoma at American Society of Hematology (ASH) annual meeting, 2020
LA CHAUX DU FONDS, Switzerland: Rhizen announces presentation of interim data from its Tenalisib + Romidepsin combination study in patients…
Read More » - India
Rhizen Pharmaceuticals Announces US FDA Acceptance of its IND Application for RP7214 in SARS-CoV-2 Infection; Phase 1 Clinical Trial of RP7214 Set to Begin Early December 2020
LA CHAUX DU FONDS, Switzerland: Rhizen announces the approval of its IND by USFDA for its oral DHODH inhibitor for…
Read More »